POLATUZUMAB VEDOTIN

Polatuzumab vedotin is an antibodydrug conjugate targeting CD79b on Bcells, delivering a cytotoxic payload for lymphoma treatment. Benefits include tumor reduction in relapsed or refractory cases. Side effects include neuropathy, neutropenia, infusion reactions, fatigue, and increased infection risk. Only GMP materials will be supplied, logistics all according to GDP.

SKU: b8dd93e65e21 Category: Tag:

Product Description


Scientific Overview

POLATUZUMAB VEDOTIN is a researchgrade biochemical compound used for advanced analytical, mechanistic and structural studies. It is often applied in laboratory environments requiring precise molecular behaviour, controlled pathway modulation and highfidelity reproducibility. The compound interacts with multiple biochemical systems depending on formulation, cell type and experimental conditions.

Mechanism of Action

Although the exact mechanism may vary by experimental model, POLATUZUMAB VEDOTIN typically exhibits activity involving:

  • Enzymatic pathway modulation through reversible or irreversible interaction with catalytic sites
  • Potential receptorlevel signaling effects influencing intracellular second messengers
  • Alterations in redox balance and oxidativestress handling systems
  • Mitochondrial functional modulation, including effects on ATP turnover and respiratorychain efficiency
  • Influence on transcriptional behaviour, geneexpression clusters and regulatory protein networks
  • Possible interaction with cytoskeletal structures affecting cellular stability and mechanical signaling

These combined effects make the compound suitable for multiaxis biochemical research.

Benefits and Applications

POLATUZUMAB VEDOTIN is commonly used for:

  • Pathway validation and mechanistic investigation
  • Bindingaffinity studies and structural modelling
  • Metabolicflux analysis and mitochondrialfunction profiling
  • Redox and oxidativestress research environments
  • Cytoskeletal and membranedynamic studies
  • Signaltransduction mapping across diverse biological systems

Risks and Safety Considerations

Potential risks associated with laboratory exposure include:

  • Oxidative imbalance or ROS accumulation
  • Mitochondrial stress or functional suppression at high concentrations
  • Unintended receptor or enzyme crossinteraction
  • Cytoskeletal destabilization or membrane disturbance
  • Dosedependent cytotoxicity under prolonged exposure

Handle only with appropriate laboratory biosafety protocols.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

C22H17Cl3N6O3

Molecular Weight

519.8 g/mol

CAS Number

2408590-36-1

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance.

Purity

Purity information is available upon request (COA).

Synonym

CWI1-2; 2408590-36-1; (E)-N',N''-Bis((E)-5-chloro-2-hydroxybenzylidene)-2-((Z)-5-chloro-2-hydroxybenzylidene)hydrazine-1-carbohydrazonhydrazide; Polatuzumab vedotin; starbld0023152

IUPAC/Chemical Name

1-[(Z)-(5-chloro-2-hydroxyphenyl)methylideneamino]-2,3-bis[(E)-(5-chloro-2-hydroxyphenyl)methylideneamino]guanidine

InChl Key

ZNYMTTHEJHXHNS-FGORHZQOSA-N

InChl Code

InChI=1S/C22H17Cl3N6O3/c23-16-1-4-19(32)13(7-16)10-26-29-22(30-27-11-14-8-17(24)2-5-20(14)33)31-28-12-15-9-18(25)3-6-21(15)34/h1-12,32-34H,(H2,29,30,31)/b26-10-,27-11+,28-12+

References

https://pubchem.ncbi.nlm.nih.gov/compound/155905758;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download